BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient.
BWXT employees trained as Nuclear Ambassadors
BWX Technologies, Inc. (BWXT) has partnered with the American Nuclear Society to offer customized ANS Nuclear Ambassadors training to BWXT employees.
BWXT Names John Lucio as Senior Director for Government Relations
BWX Technologies, Inc. has hired John Lucio as a senior director for government relations.
BWXT Named First Member of GE Vernova Nuclear’s Small Modular Reactor Supplier Group
BWXT Canada Ltd., a subsidiary of BWX Technologies, Inc. has been selected as the first qualified supply chain company to join the GE Vernova nuclear business’ supplier group that will advance the global deployment of the BWRX-300 small modular reactor (SMR).
BWXT Announces Expansion of Cambridge Manufacturing Plant to Support Global Nuclear Power Market
BWX Technologies, Inc. (NYSE: BWXT) announced an investment to expand its Cambridge manufacturing plant.
BWXT Canada Joins Canadians for CANDU® Campaign
BWXT Canada Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), has joined the Canadians for CANDU Campaign.
UK Space Agency Awards Space Reactor Development Project to BWXT and Rolls-Royce
BWX Technologies, Inc. announced that it and Rolls-Royce have secured funding for Phase 2 of the UK Space Agency’s International Bilateral Fund (IBF).
BWX Technologies to Announce First Quarter 2024 Results on Monday, May 6
LYNCHBURG, Va. -- BWX Technologies, Inc. (NYSE: BWXT) will issue a press release detailing first quarter 2024 results on Monday, May 6, 2024.
BWXT Releases 2024 Sustainability Report
BWX Technologies, Inc. (NYSE: BWXT) has released its 2024 Sustainability Report.